- Home
- KRC vs ACLX Comparison
KRC vs ACLX Comparison
Compare KRC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRC
- ACLX
- Stock Information
- Founded
- KRC 1947
- ACLX 2015
- Country
- KRC United States
- ACLX United States
- Employees
- KRC N/A
- ACLX N/A
- Industry
- KRC Real Estate Investment Trusts
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- KRC Real Estate
- ACLX Health Care
- Exchange
- KRC Nasdaq
- ACLX Nasdaq
- Market Cap
- KRC 4.9B
- ACLX 4.1B
- IPO Year
- KRC 1997
- ACLX 2022
- Fundamental
- Price
- KRC $43.62
- ACLX $75.20
- Analyst Decision
- KRC Hold
- ACLX Strong Buy
- Analyst Count
- KRC 11
- ACLX 13
- Target Price
- KRC $38.82
- ACLX $114.75
- AVG Volume (30 Days)
- KRC 1.2M
- ACLX 526.7K
- Earning Date
- KRC 10-27-2025
- ACLX 11-06-2025
- Dividend Yield
- KRC 4.95%
- ACLX N/A
- EPS Growth
- KRC 9.52
- ACLX N/A
- EPS
- KRC 1.84
- ACLX N/A
- Revenue
- KRC $1,137,053,000.00
- ACLX $56,979,000.00
- Revenue This Year
- KRC N/A
- ACLX N/A
- Revenue Next Year
- KRC $0.73
- ACLX $174.18
- P/E Ratio
- KRC $23.73
- ACLX N/A
- Revenue Growth
- KRC 2.26
- ACLX N/A
- 52 Week Low
- KRC $27.07
- ACLX $47.86
- 52 Week High
- KRC $43.78
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- KRC 71.84
- ACLX 59.74
- Support Level
- KRC $40.64
- ACLX $70.11
- Resistance Level
- KRC $42.83
- ACLX $78.61
- Average True Range (ATR)
- KRC 0.82
- ACLX 2.62
- MACD
- KRC 0.10
- ACLX 0.52
- Stochastic Oscillator
- KRC 96.84
- ACLX 70.63
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.